Abstract
Buspirone was compared with imipramine and placebo in the treatment of panic disorder in an 8-week, double-blind controlled study of 52 randomly assigned patients. The side effect profile of buspirone was less disruptive than that of imipramine. Buspirone was not significantly superior to placebo in its antipanic or anxiolytic effects in panic disorder patients.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Agoraphobia / drug therapy
-
Anxiety Disorders / drug therapy*
-
Anxiety Disorders / psychology
-
Arousal / drug effects
-
Buspirone / therapeutic use*
-
Double-Blind Method
-
Fear / drug effects*
-
Female
-
Follow-Up Studies
-
Humans
-
Imipramine / therapeutic use
-
Male
-
Panic / drug effects*
-
Phobic Disorders / drug therapy*
-
Phobic Disorders / psychology
-
Psychiatric Status Rating Scales
-
Randomized Controlled Trials as Topic
-
Single-Blind Method